Clinical trial
A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in…
NCT00130325 · Medical Research Council Unit, The Gambia, Other · Completed
Key facts
| NCT number | NCT00130325 |
|---|---|
| Title | A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts |
| Official title | A Double Blind Placebo-controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts |
| Acronym | IRS |
| Lead sponsor | Medical Research Council Unit, The Gambia, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | Isoniazid, Placebo of Isoniazid tablets 300mg |
| Enrollment | 214 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Aug 15, 2005 |
| Last update posted | Jan 13, 2010 |
| Countries | The Gambia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: